As the fourth most frequently diagnosed and fourth most deadly cancer in women worldwide, cervical cancer carries a high disease burden in the US (1). While screening has improved the early detection of cervical cancer, up to 16% initially present with metastatic disease (2), whose 5-year survival rate is dismal at 17% (3). Of those whose cancer is detected in earlier stages, 15-61% go on to develop metastatic cervical cancer within the first 2 years following completion of initial treatment (2).
Using MarketScan™ claims data, Value Analytics Labs collaborated with the Seagen HEOR team to design and conduct a real-world evidence study to understand the predictors of treatment continuation and the geographical differences in cervical cancer burden. Our findings were incorporated into the Cervical Cancer Geo-Analyzer, an open access, web-based, interactive tool to visualize geographical areas in the US where cervical cancer education or healthcare resource needs are high.
The tool (4) and the study findings (5) that support the tool were presented at the 2022 American Society of Clinical Oncology’s annual meeting in Chicago.